DDInter1592 DDInter1731
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Sunitinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Indinavir
Indinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is regulated by {v} (Gene) CAMK2G
CAMK2G {u} (Gene) is bound by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is downregulated by {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) is treated by {v} (Compound) Sunitinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sunitinib
Rifapentine (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Sunitinib (Compound)
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Sunitinib (Compound)
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Sunitinib
Rifapentine (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Indinavir (Compound) and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Sunitinib (Compound)
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is regulated by CAMK2G (Gene) and CAMK2G (Gene) is bound by Sunitinib (Compound)
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Sunitinib (Compound)
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is downregulated by pancreatic cancer (Disease) and pancreatic cancer (Disease) is treated by Sunitinib (Compound)
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)